Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 367

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 19
Chunk 367
---

Interest income 694 2,007 1,820
Exchange differences, net - 61 51
694 2,068 1,871

  Financial expenses  

                                 Year ended December 31,                                   
                                 Year ended December 31,                                   
                                 2022                                                      
                                 2022                                                      
 ───────────────────────────────────────────────────────────────────────────────────────────
                                 in USD thousands                                          
  Interest expense                                            1,786      2,144      9,074  
  Bank commissions                                            26         25         45     
  Exchange differences, net                                   346        -          -      
                                                              2,158      2,169      9,119  

F - 52

BioLineRx Ltd.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE 21 - SUBSEQUENT EVENT - REGISTERED DIRECT OFFERING

In January 2025, the Company completed a registered direct offering to certain institutional investors of858,303ADSs and391,967pre-funded warrants to purchase ADSs. Each ADS and pre-funded warrant was sold at a purchase price of $8.00and $7.996, respectively. The Company also issued to the investors unregistered ordinary warrants to purchase an aggregate of1,250,000ADSs. The pre-funded warrants are exercisable immediately, do not expire until exercised in full, and have an exercise price of $0.004per ADS. The ordinary warrants are exercisable immediately, expirefour yearsfrom the date of issuance, and have an exercise price of $8.00per ADS. A holder of the pre-funded or ordinary warrants cannot exercise such warrants if the holder, together with its affiliates, would beneficially own in excess of 4.99% (or 9.99% at the election of the holder) of the outstanding share capital of the Company immediately after giving effect to such exercise.

In addition, the Company granted to the placement agent in the offering, as part of the placement fee, warrants to purchase62,500ADSs. These warrants are exercisable immediately, expirefive yearsfrom the date of issuance and have an exercise price of $10.00per ADS.

Gross proceeds from the offering totaled $10.0million, with net proceeds of $8.9million, after deducting fees and expenses.

The offering purchase agreements include lock-up, variable rate transaction, warranty, indemnification, and other provisions customary for transactions of this nature.

F